SRNE News and Press, Sorrento Therapeutics Inc. From 11/19/20

In this video from Motley Fool Live , which was recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , talks about how the biotech got its start. The company's focus on antibodies has helped it pivot from a previous focus on de...

In its recent 13F filing, Coatue Management reported a significant growth in total fund portfolio value to $19.05B from $11.37B in the earlier quarter.Notable buys: Best Buy (BBY), Expedia (EXPE), American Eagle Outfitters (AEO), L Brands (LB) and Gap (GPS).Q3 portfolio activity included nume...

Palm Beach, FL – November 17, 2020 – The pandemic has wreaked havoc across the healthcare industry, and has led medical researchers to redirect all their might towards developing test kits and antidotes for coronavirus. The growth of the global covid-19 detection kits market r...

As the coronavirus vaccine race continues, investors are increasingly ditching less prominent drugmakers exhibiting slow progress and/or financial woes; Inovio Pharmaceuticals (NASDAQ: INO) and Sorrento Therapeutics (NASDAQ: SRNE) are down between 8% and 36%, respectively,...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) were jumping 11.2% higher as of 11:09 a.m. EST on Wednesday. The nice gain came after the company announced that it's filing an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin an earl...

Sorrento Therapeutics ([[SRNE]] +5.7%) has filed an Investigational New Drug ((IND)) application with the FDA seeking sign-off on the commencement of clinical development of an intranasal formulation of STI-2099, dubbed COVI-DROPS, a neutralizing anti-SARS-CoV-2 antibody, for the potential ou...

IND filing today for STI-2099 (COVI-DROPS™) for a phase 1 safety and pharmacokinetic study in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of COVI-AMG™. Initial trial is expected to be followed by ...

Sorrento Therapeutics (NASDAQ: SRNE) isn't letting Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) grab all the headlines about the healthcare industry's battle against the coronavirus. On Monday, Sorrento announced it has submitted an Investigational New Drug (IND) a...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) fell 37.8% in October according to data provided by S&P Global Market Intelligence . Shares peaked on Oct. 13 in anticipation of a research and development presentation to go over the company's vast array of potential COVID-19 p...

Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...